Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz, MD, FACP

BOSTON and LONDON, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology ...

Akari Therapeutics Announces Launch of CEO Corner Platform

CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline progress Provides interested parties with the ability to ask questions and submit topics for ...

Akari Therapeutics Plc: Akari Therapeutics Announces Formation of Scientific Advisory Board and Inaugural Appointment of Renowned Medical Oncologist, Sara A. Hurvitz…

Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates ...
The Globe and Mail

Akari Therapeutics Files Two New Patents for Immuno-Oncology Mode of Action for Novel ADC Platform Utilizing Spliceosome Modulating Payload PH1

BOSTON and LONDON, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced ...
India West

Ten Indian American Scientists Awarded for Contributions in Cancer Research

NEW ORLEANS, LA – Ten Indian American scientists were honored for their outstanding contributions in cancer research by the Society of American Asian Scientists in Cancer Research (SAASCR) on April 10 ...
The American Journal of Managed Care

ZRSR2 Loss Alone Does Not Drive JAK2 V617F MPN Progression

Mutations in ZRSR2 have been linked with disease progression in patients with JAK2 V617R – driven myeloproliferative neoplasms (MPNs), but a new report suggests that loss of ZRSR2 alone is not ...